Launch week offerEnds in00h00m00s

annual Promonthly Pro

Edmond Kwan

Senior Research Fellow

MONASH UNIVERSITY

Australia

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Professors in Australia Professors in Biostatistics Biostatistics professors in Australia

Articles (14)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Collaborators (13)

Amir Iravani

Associate Professor

University of Washington

UNITED STATES

View details

Siavash Foroughi

Walter and Eliza Hall Institute of Medical Research

AUSTRALIA

View details

Alison Zhang

Macquarie University

AUSTRALIA

View details

Vinod Vijay Subhash

University of New South Wales

AUSTRALIA

View details

Takayuki Sumiyoshi

Kyoto University Hospital

JAPAN

View details

Andrew Martin

Professor of Biostatistics

University of Sydney

AUSTRALIA

View details

Anthony M. Joshua

Head of Department

University Health Network

CANADA

View details

Johan Lindberg

Karolinska University Hospital

SWEDEN

View details

Matti Nykter

Professor

University of Tampere

FINLAND

View details

Roslyn Francis

Director, Professor

University of Western Australia

AUSTRALIA

View details

David Takeda

Principal Investigator

National Institutes of Health

UNITED STATES

View details

Robert Kirby

Professor

University of Utah

UNITED STATES

View details

Maarten IJzerman

Full professor

Erasmus University Rotterdam

NETHERLANDS

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Edmond Kwan

Research Interests

Make your next move.

Explore related searches

Articles (14)

Plasma cell-free DNA chromatin immunoprecipitation profiling depicts phenotypic and clinical heterogeneity in advanced prostate cancer

Lutetium-177–PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial

Safety and Efficacy of 20 Cycles of [177Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

Therapy-Related Myeloid Neoplasms After [177Lu]Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Series

…But Words Will Never Hurt Me

Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer.

Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial

Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping

Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer

BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype

Multi-Omic Integration of Blood-Based Tumor-Associated Genomic and Lipidomic Profiles Using Machine Learning Models in Metastatic Prostate Cancer

A generalizable machine learning framework for classifying DNA repair defects using ctDNA exomes

Prostate-specific membrane antigen positron emission tomography-computed tomography use prior to systemic therapy in metastatic castration-resistant prostate cancer

Real-world clinical outcomes and cost estimates of metastatic castration-resistant prostate cancer treatment

Collaborators (13)

Amir Iravani

Siavash Foroughi

Alison Zhang

Vinod Vijay Subhash

Takayuki Sumiyoshi

Andrew Martin

Anthony M. Joshua

Johan Lindberg

Matti Nykter

Roslyn Francis

David Takeda

Robert Kirby

Maarten IJzerman

Make your next move.